Document is current
Any future updates will be listed below
-
Authors
Trammell, Samuel A. J.
Schmidt, Mark S.
Weidemann, Benjamin J.
Redpath, Philip
Jaksch, Frank
Dellinger, Ryan W.
Li, Zhonggang
Abel, E. Dale
Migaud, Marie E.
Brenner, Charles https://orcid.org/0000-0002-4955-3226
- License Information
-
More Information
Article History
Received: 30 January 2016
Accepted: 12 August 2016
First Online: 10 October 2016
Change Date: 15 November 2016
Change Type: Update
Change Details: This paper was updated shortly after publication, following a technical error that resulted in the Supplementary Data links connecting to the wrong files. The error has now been corrected in the HTML. The PDF has been correct from the time of publication.
Competing interests
: F.J., R.W.D. and C.B. own stock in ChromaDex, the supplier of NR and sponsor of the clinical study. F.J. and R.W.D. are employees of ChromaDex. M.E.M. has received research grants and serves as a consultant for ChromaDex. C.B. has received a research grant and serves on the scientific advisory board of ChromaDex. S.A.J.T. and C.B. have an intellectual property interest in detecting NAAD as a biomarker of elevated NAD metabolism. C.B. is the chief scientific adviser of ProHealthspan, which sells NR supplements. The remaining authors declare no competing financial interests.
